Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
Study Details
Study Description
Brief Summary
This phase I trial is looking to determine if hypofractionated radiation therapy can be given safely after surgery for intermediate-risk head and neck cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
PRIMARY OBJECTIVE:
- To determine if a hypofractionated postoperative radiotherapy (H-PORT) schedule for patients with intermediate-risk head and neck cancer (squamous cell carcinoma of the oral cavity, oropharynx, or larynx) who have undergone surgery is safe and feasible for further evaluation in a phase II clinical trial.
SECONDARY OBJECTIVES:
-
To assess H-PORT treatment-related and unrelated adverse events during treatment and within one year after treatment completion.
-
To assess H-PORT tolerability and compliance, as measured by treatment interruptions and discontinuations, and to assess the reasons for those modifications.
ARM I: Patients undergo surgery per standard of care followed by hypofractionated radiotherapy. Patients receive 50 Gy over 4 weeks (i.e., 2.5 Gy per day x 20 fractions). Radiation therapy should start after there is adequate healing and no evidence of gross residual/recurrent cancer.
Patients are followed up at 1 month, 3 months, 6 months and 12 months post H-PORT therapy.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Hypofractionated Postoperative Radiotherapy (H-PORT) H-PORT of 50 Gy given over 4 weeks. |
Radiation: Hypofractionated Postoperative Radiotherapy
Hypofractionated Postoperative Radiation Therapy
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Dose-Limiting Toxicity (DLT) [From the start of H-PORT up 12 months post-radiation]
All grades are based on Common Terminology Criteria for Adverse Events (CTCAE v.5). H-PORT in this population will be deemed safe if 0-2 patients out of the first 12 evaluable patients experience DLTs. Should 3 or more patients experience DLTs at any time point during the DLT evaluation period, then accrual to the trial will be stopped, if applicable. Once 12 evaluable eligible patients have completed their DLT assessment, the rate of unacceptable DLTs and 95% confidence interval will be summarized using proportions for binary outcomes and the exact binomial method.
Secondary Outcome Measures
- Incidence of Adverse Events [From the start of H-PORT up to 12 months post-radiation]
Adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0. Counts and percentages will be provided for the worst grade AE experienced.
- Rate of radiation interruptions [From the start to the end of H-PORT, assessed up to 4 weeks]
Counts and percentages will be provided for treatment interruptions.
- Rate of radiation discontinuations [From the start to the end of H-PORT, assessed up to 4 weeks]
Counts and percentages will be provided for treatment discontinuations.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Pathologically (histologically) proven diagnosis of squamous cell carcinoma (including variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma Not Otherwise
Specified (NOS), etc.) of the head/neck (oral cavity, oropharynx or larynx); Note:
Hypopharynx primaries are excluded because these patients have both a poor prognosis and high likelihood of post-radiation complications.
-
Clinical stage II, III or IVA squamous cell carcinoma of the oral cavity, oropharynx or larynx (AJCC 8th edition), including no distant metastases.
-
General history and physical examination prior to registration;
-
Chest X-ray (at a minimum) or chest CT scan (with or without contrast) or PET/CT of chest (with or without contrast) prior to registration.
-
Total resection of the patient's cancer (i.e., no residual disease after total resection of the patient's cancer ).
-
One or more indications for postoperative radiotherapy, based upon pathologic findings:
-
Perineural invasion;
-
Lymphovascular invasion;
-
Single lymph node ≥ 3 cm or ≥ 2 lymph nodes (no extracapsular extension);
-
Close margin(s) of resection (close margins defined as cancer extending to within 5 mm of a surgical margin);
-
Pathologically confirmed T3 or T4a primary tumor;
-
T2 oral cavity cancer with ≥ 5 mm depth of invasion
-
Zubrod Performance Status 0-1
-
Age 18-75
-
Negative pregnancy test within 14 days prior to registration for women of childbearing potential
-
Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control.
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety assessment of the investigational regimen are eligible for this trial.
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry.
Exclusion Criteria:
-
Recurrence of the study cancer.
-
History of systemic lupus erythematosus or systemic sclerosis (scleroderma).
-
Pregnancy and individuals unwilling to discontinue nursing.
-
Feeding tube (gastric or jejuno) at the time of registration.
-
Anticipated need for high-dose systemic chemotherapy (e.g., high dose q3-week cisplatin), multiple systemic therapy agents or immunotherapy. Weekly single-agent systemic therapy with cisplatin, carboplatin, or cetuximab is allowable.
-
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields; prior chemotherapy for study cancer is not allowed.
-
Per the operative and/or pathology report, positive margin(s) [defined as tumor present at the cut or inked edge of the tumor], nodal extracapsular extension, and/or gross residual disease after surgery; Note: Patients whose tumors had focally positive margins in the main specimen but negative margins from re-excised samples in the region of the positive margin are eligible.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- American College of Radiology
- RTOG Foundation
Investigators
- Principal Investigator: Etta Pisano, MD, American College of Radiology
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ACR 3518